Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director · Chief Scientific Officer | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed May 3, 2024 22:28 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003827 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,968 shares purchased on May 15, 2023 and 2,088 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 172,585 | $9.33 | $1,610,097.24 |
DisclosureSEC source: 0001562180-23-008571 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,606 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.155 USD to $9.595 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006454 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,602 | $8.90 | $14,265.65 |
DisclosureSEC source: 0001562180-23-003920 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,191 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003920 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003920 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001562180-22-006029 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 15,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003664 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2025-05-01 F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 23:20 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-21-007369 · primarydocument.xml · derivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,352 Underlying: Common Stock · 25,000 shares Expires 2028-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on September 10, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 23:20 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 147,585 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-21-007369 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 147,585 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option vested on July 27, 2018 and 1/48th of the shares subject to the option vested each month thereafter. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 23:20 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 25,000 | $0.45 | $11,250.00 |
DisclosureSEC source: 0001562180-21-007369 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 23:20 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 147,585 | $0.18 | $26,565.30 |
DisclosureSEC source: 0001562180-21-007369 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:05 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 38 | $19.61 | $745.18 |
DisclosureSEC source: 0001562180-21-007134 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:05 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 441 | $19.07 | $8,410.22 |
DisclosureSEC source: 0001562180-21-007134 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $19.52, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,562 | $19.51 | $167,073.73 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 7 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479 F8 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,681 | $20.43 | $75,195.47 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 6 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,041 F7 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.29 to $20.82, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 15,595 | $19.82 | $309,043.00 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,722 F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.29 to $20.285, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 580 | $20.21 | $11,723.08 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,317 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $20.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 11,746 | $19.70 | $231,446.71 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,897 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.095 to $20.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 12,712 | $20.30 | $258,030.72 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,643 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.17 to $20.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 16,864 | $19.94 | $336,274.91 |
DisclosureSEC source: 0001562180-21-007025 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.17 to $20.165, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 00:11 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 9,017 | $20.16 | $181,824.20 |
DisclosureSEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,219 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.84 to $20.645, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 00:11 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 13,036 | $19.62 | $255,783.27 |
DisclosureSEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,236 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $20.19, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 00:11 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 6 | $20.70 | $124.20 |
DisclosureSEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,272 Read SEC document |
| November 04, 2021 Filed Nov 9, 2021 00:11 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,392 | $19.76 | $146,091.79 |
DisclosureSEC source: 0001562180-21-006901 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,278 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.415, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,119 | $19.42 | $21,725.83 |
DisclosureSEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,670 F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.36 to $19.53, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,243 | $18.84 | $79,944.48 |
DisclosureSEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,789 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.345 to $19.34, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 20,822 | $17.98 | $374,425.37 |
DisclosureSEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,032 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.325 to $18.32, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 17,519 | $17.43 | $305,359.67 |
DisclosureSEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,854 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.025 to $17.995, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 469 | $18.02 | $8,453.54 |
DisclosureSEC source: 0001562180-21-006811 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,373 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:48 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 126 | $18.00 | $2,268.00 |
DisclosureSEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,842 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 23:48 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,307 | $18.13 | $23,698.13 |
DisclosureSEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 23:48 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,749 | $18.18 | $104,516.82 |
DisclosureSEC source: 0001562180-21-006498 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,275 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 22:51 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,270 | $18.02 | $22,885.40 |
DisclosureSEC source: 0001562180-21-006455 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 22:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,902 | $18.15 | $107,121.30 |
DisclosureSEC source: 0001562180-21-006391 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,294 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 22:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 13,018 | $18.56 | $241,614.08 |
DisclosureSEC source: 0001562180-21-006391 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,196 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.62, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 22:00 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,108 | $18.03 | $38,007.24 |
DisclosureSEC source: 0001562180-21-006391 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,214 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 22:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,404 | $18.26 | $98,677.04 |
DisclosureSEC source: 0001562180-21-006323 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,322 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 22:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 100 | $18.00 | $1,800.00 |
DisclosureSEC source: 0001562180-21-006323 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,726 Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 274 | $18.00 | $4,932.00 |
DisclosureSEC source: 0001562180-21-006323 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,826 Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 23:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 618 | $17.47 | $10,796.46 |
DisclosureSEC source: 0001562180-21-006168 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,100 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.37 to $17.71, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 23:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 11,226 | $16.83 | $188,933.58 |
DisclosureSEC source: 0001562180-21-006168 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,718 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.36 to $17.36, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 23:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 14,610 | $17.30 | $252,753.00 |
DisclosureSEC source: 0001562180-21-006168 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.985 to $17.93, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 27, 2021 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 17 | $18.48 | $314.16 |
DisclosureSEC source: 0001562180-21-006116 · primarydocument.xml · nonDerivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,554 Read SEC document |
| September 27, 2021 Filed Sep 27, 2021 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 11,594 | $17.98 | $208,460.12 |
DisclosureSEC source: 0001562180-21-006116 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,571 F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.47 to $18.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 20,100 | $18.16 | $365,016.00 |
DisclosureSEC source: 0001562180-21-006116 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,165 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 5,072 | $19.42 | $98,498.24 |
DisclosureSEC source: 0001562180-21-006116 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,265 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.97. to $19.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 23:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 21,763 | $18.34 | $399,133.42 |
DisclosureSEC source: 0001562180-21-006116 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $17.93 to $18.925, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0001562180-21-005463 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.